PAPAIJV
ELV icon

Paragon Associates & Paragon Associates II Joint Venture’s Elevance Health ELV Stock Holding History

Paragon Associates & Paragon Associates II Joint Venture’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-20,000
Closed -$6.04M – 17
2019
Q4 		$6.04M Buy
+20,000
New +$5.5M 3.39% 9
2019
Q3 		– Sell
-12,500
Closed -$3.53M – 25
2019
Q2 		$3.53M Buy
+12,500
New +$3.41M 2.72% 15

Other funds holding ELV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paragon Associates & Paragon Associates II Joint Venture's ELV Position: Q1 2020 in Review

Paragon Associates & Paragon Associates II Joint Venture sold out of Elevance Health (ELV) in Q1 2020, closing a stake of 20,000 shares — an estimated $6.04M sold.

Paragon Associates & Paragon Associates II Joint Venture first reported a position in ELV in Q2 2019 and held it in 2 quarters. The position peaked at $6.04M in Q4 2019. 1,052 funds tracked by Wall St. Rank hold ELV as of Q1 2020.

  • Paragon Associates & Paragon Associates II Joint Venture reported no remaining Elevance Health position as of Q1 2020 after selling out during the quarter.
  • Paragon Associates & Paragon Associates II Joint Venture sold 20,000 Elevance Health shares in Q1 2020, an estimated $6.04M.
  • Paragon Associates & Paragon Associates II Joint Venture first reported a position in Elevance Health in Q2 2019 and held it in 2 quarters.
  • Paragon Associates & Paragon Associates II Joint Venture's Elevance Health position peaked at $6.04M in Q4 2019.
  • 1,052 funds tracked by Wall St. Rank held Elevance Health as of Q1 2020.

Based on Paragon Associates & Paragon Associates II Joint Venture's 13F filing for Q1 2020, filed 15 May 2020.